CO2022002804A2 - Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos - Google Patents

Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Info

Publication number
CO2022002804A2
CO2022002804A2 CONC2022/0002804A CO2022002804A CO2022002804A2 CO 2022002804 A2 CO2022002804 A2 CO 2022002804A2 CO 2022002804 A CO2022002804 A CO 2022002804A CO 2022002804 A2 CO2022002804 A2 CO 2022002804A2
Authority
CO
Colombia
Prior art keywords
nsd2
purinamines
antineoplastics
piperidinyl
inhibitors
Prior art date
Application number
CONC2022/0002804A
Other languages
English (en)
Inventor
Ce Wang
Haibing Deng
Jinbiao Liu
Counde Oyang
Qitao Xiao
Guoliang Xun
Haiqiang Zeng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2022002804A2 publication Critical patent/CO2022002804A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula (I): (I) o un enantiómero, una mezcla enantiomérica o una sal farmacéuticamente aceptable de este; en donde las variables son tal como se definieron en la presente. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos; y métodos para usar tales compuestos para tratar una enfermedad o afección mediada por la proteína nuclear 2 que contiene el dominio SET (NSD2).
CONC2022/0002804A 2019-08-14 2022-03-10 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos CO2022002804A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Publications (1)

Publication Number Publication Date
CO2022002804A2 true CO2022002804A2 (es) 2022-04-08

Family

ID=72145436

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002804A CO2022002804A2 (es) 2019-08-14 2022-03-10 Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos

Country Status (13)

Country Link
US (2) US11420970B1 (es)
EP (1) EP4013755A1 (es)
JP (1) JP2022544946A (es)
KR (1) KR20220047330A (es)
CN (1) CN114585622A (es)
AU (1) AU2020328919A1 (es)
BR (1) BR112022002520A2 (es)
CA (1) CA3144542A1 (es)
CO (1) CO2022002804A2 (es)
EC (1) ECSP22019360A (es)
IL (1) IL289754A (es)
MX (1) MX2022001784A (es)
WO (2) WO2021026803A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133201A1 (en) * 2022-01-05 2023-07-13 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
WO2023225154A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20240002385A1 (en) * 2022-05-18 2024-01-04 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230026A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100892614B1 (ko) * 2001-04-17 2009-04-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 유도체
AU2003264017B2 (en) * 2002-08-08 2010-05-27 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
CA2497765A1 (en) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
KR101793300B1 (ko) * 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用

Also Published As

Publication number Publication date
ECSP22019360A (es) 2022-04-29
IL289754A (en) 2022-03-01
CN114585622A (zh) 2022-06-03
MX2022001784A (es) 2022-04-18
BR112022002520A2 (pt) 2022-05-10
WO2021028854A1 (en) 2021-02-18
EP4013755A1 (en) 2022-06-22
KR20220047330A (ko) 2022-04-15
US11420970B1 (en) 2022-08-23
JP2022544946A (ja) 2022-10-24
US20230002388A1 (en) 2023-01-05
AU2020328919A1 (en) 2022-02-17
CA3144542A1 (en) 2021-02-18
WO2021026803A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CL2021001132A1 (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
CL2019002204A1 (es) Compuestos inhibidores del vih.
UY38057A (es) Inhibidores de sarcómero cardíaco
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
CO2021014210A2 (es) Compuestos de pirrol
CL2022002368A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
UY37569A (es) Inhibidores del inmunoproteasoma
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR123281A1 (es) Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
CL2022000320A1 (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones
CO2021017202A2 (es) Compuestos tricíclicos
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR122332A1 (es) Compuestos inhibidores de la autofagia de fenilaminopirimidina amida y composiciones que los comprenden
UY39466A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis
BR112022014728A2 (pt) Composto, composição farmacêutica, e, método para tratar uma doença ou condição
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias